Semaglutide (Ozempic) vs Tirzepatide (Mounjaro)

The most important clinical evidence comparing Ozempic and Mounjaro comes from SURPASS-2, a phase 3, open-label, 40-week trial that directly compared tirzepatide (5 mg, 10 mg, and 15 mg) against semaglutide 1 mg in 1,879 adults with type 2 diabetes inadequately controlled on metformin ^[3].

For HbA1c reduction (the primary endpoint), all three tirzepatide doses were superior to semaglutide 1 mg ^[3]. Mean HbA1c reductions from a baseline of approximately 8.3% were: tirzepatide 5 mg: -2.01%; tirzepatide 10 mg: -2.24%; tirzepatide 15 mg: -2.30%; semaglutide 1 mg: -1.86%. The percentage of patients achieving HbA1c below 7% was 82-92% with tirzepatide versus 79% with semaglutide ^[3].

For weight loss (a key secondary endpoint), the differences were even more pronounced ^[3]. Mean weight changes were: tirzepatide 5 mg: -7.6 kg; tirzepatide 10 mg: -9.3 kg; tirzepatide 15 mg: -11.2 kg; semaglutide 1 mg: -5.7 kg. At the highest dose, tirzepatide nearly doubled the weight loss of semaglutide ^[3].

Important caveats: SURPASS-2 compared tirzepatide to semaglutide 1 mg, not the 2 mg dose of Ozempic that later became available ^[3]. Additionally, the trial was open-label, meaning patients and investigators knew which treatment was being administered, which can influence reported outcomes.

Beyond SURPASS-2, the broader SURPASS program (SURPASS-1 through SURPASS-5) consistently showed tirzepatide produced HbA1c reductions of 1.87% to 2.58% and weight loss of 5.4 to 12.9 kg across various patient populations and comparators ^[4][6][7]. The SUSTAIN program for semaglutide showed HbA1c reductions of 1.2% to 1.8% and weight loss of 3.5 to 6.5 kg ^[1][5].

Based on the available evidence, Mounjaro appears to produce greater glycemic improvement and substantially more weight loss than Ozempic, though both represent major advances over older diabetes therapies ^[3][9].

Both Ozempic and Mounjaro produce gastrointestinal side effects as the most common adverse events, which is expected given their mechanisms of action involving the incretin system ^[1][2].

In the SURPASS-2 head-to-head trial, gastrointestinal adverse events occurred at similar rates between tirzepatide and semaglutide 1 mg ^[3]. Nausea was reported by 17-22% of tirzepatide patients versus 18% of semaglutide patients. Diarrhea occurred in 13-16% versus 12%. Vomiting was reported in 6-10% versus 8%. Decreased appetite occurred in 5-10% versus 7%. Treatment discontinuation due to adverse events was 4-7% for tirzepatide versus 4% for semaglutide ^[3].

Notably, while the side effect rates were similar, tirzepatide at higher doses produced significantly greater efficacy ^[3]. This suggests a potentially favorable benefit-to-risk ratio for tirzepatide ^[9].

Both medications carry boxed warnings for thyroid C-cell tumors based on animal studies and are contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2 ^[1][2]. Both carry warnings for pancreatitis, acute gallbladder disease, hypoglycemia (especially with insulin or sulfonylureas), acute kidney injury, hypersensitivity reactions, and diabetic retinopathy complications ^[1][2].

One difference is that injection site reactions appear slightly more common with tirzepatide (ranging from 3-7% across doses) compared to semaglutide (approximately 0.2-1%) ^[2][3]. These reactions are generally mild and transient.

Both Ozempic and Mounjaro are premium-priced brand-name medications without generic alternatives currently available ^[1][2].

At list price, Ozempic costs approximately $935-$1,000 per month ^[1]. Mounjaro is priced at approximately $1,023-$1,100 per month ^[2]. These prices are relatively comparable, though actual out-of-pocket costs vary widely by insurance plan.

Both medications are generally covered by commercial insurance plans for their FDA-approved indication of type 2 diabetes, though prior authorization requirements are common. Formulary placement (preferred vs. non-preferred tier) varies significantly by plan and can affect copay amounts substantially.

Novo Nordisk offers the Ozempic Savings Card, which can reduce costs to as low as $25 per fill for eligible commercially insured patients ^[1]. Eli Lilly offers the Mounjaro Savings Card with similar reductions for eligible patients ^[2].

Medicare Part D covers both medications for type 2 diabetes, though plan-specific formulary placement and tier assignments affect out-of-pocket costs under the benefit structure. The Inflation Reduction Act's insulin and drug price provisions may indirectly influence coverage decisions.

For uninsured patients, both manufacturers have patient assistance programs. Patients should explore all available options with their healthcare provider and pharmacist.

Both Ozempic and Mounjaro are administered as once-weekly subcutaneous injections, providing comparable convenience for most patients ^[1][2].

Ozempic uses Novo Nordisk's FlexTouch pen technology and is available in three pen configurations (0.25/0.5 mg, 1 mg, and 2 mg) ^[1]. Mounjaro uses Eli Lilly's single-use autoinjector device, available in six dose strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg), with each autoinjector used once and discarded ^[2].

Mounjaro's autoinjector design is often considered simpler to use than traditional pen injectors because it requires fewer steps — the patient presses the device against the skin and clicks a button ^[2]. Ozempic's pen requires dialing the dose and pressing a plunger ^[1].

Both medications should be refrigerated before first use. Ozempic pens can be stored at room temperature for up to 56 days after first use, while Mounjaro autoinjectors can be stored at room temperature for up to 21 days ^[1][2]. The injection can be given in the abdomen, thigh, or upper arm with either product ^[1][2].

Choosing between Ozempic and Mounjaro for type 2 diabetes management involves weighing clinical evidence, individual patient factors, and practical considerations including insurance coverage and availability ^[1][2].

Based on the SURPASS-2 head-to-head trial, Mounjaro demonstrated superior HbA1c reduction and substantially greater weight loss compared to Ozempic (semaglutide 1 mg) ^[3]. For patients for whom both glycemic control and weight loss are important treatment goals, this evidence favors Mounjaro. The dual GIP/GLP-1 mechanism may provide advantages that a single GLP-1 agonist approach does not ^[9].

However, Ozempic has a longer track record, with FDA approval since 2017 and extensive real-world safety data ^[1]. The SUSTAIN-6 cardiovascular outcomes trial demonstrated a 26% reduction in MACE events ^[5]. While tirzepatide cardiovascular outcomes data from the SURPASS-CVOT trial are anticipated, long-term cardiovascular outcomes data for Mounjaro in type 2 diabetes patients are still being established ^[10].

Insurance coverage and formulary access may ultimately drive the decision for many patients. Some plans may prefer one medication over the other, and prior authorization requirements can differ. Availability has also been a factor, as both medications have experienced supply constraints ^[8].

Patients who are already well-controlled on one medication generally should not switch solely based on comparative trial data without discussing the potential risks and benefits of a transition with their provider.

This information is intended for educational purposes only and does not constitute medical advice. Consult your healthcare provider to determine which medication is best suited to your individual health needs.